News Headlines
-
Alembic Pharmaceuticals Strengthens Strategic Collaboration With DifGen To Expand Its Complex Generics Portfolio In The US
11/5/2026
Building on their existing relationship, including the joint venture in Canada, the expanded collaboration combines DifGen’s development and US manufacturing capabilities with Alembic’s established US commercial platform.
-
Vector BioMed Selected As Top Lentiviral Vector Design And Manufacturing Company
11/5/2026
Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced that it has been named Lentiviral Vector Design and Manufacturing Company of the Year in Asia 2026 by Life Sciences Review.
-
ProBio Successfully Completes NMPA Pre-Approval Inspection For Biologics Manufacturing Facility In Nanjing, China
11/4/2026
ProBio Inc., a global contract research, development and manufacturing organization (CRDMO), today announced the successful completion of a Pre-Approval Inspection (PAI) by China's National Medical Products Administration (NMPA) at its biologics manufacturing facility in Nanjing, China, marking an important milestone in the company's continued expansion of its biologics GMP manufacturing capabilities and regulatory readiness.
-
ProBio's AAV Manufacturing Excellence Powers UC Irvine And GlyTR Therapeutics First‑In‑Class Pan-Cancer CAR‑T Program
11/4/2026
The University of California, Irvine (UC Irvine) School of Medicine and GlyTR Therapeutics have developed a next‑generation AAV‑mediated CAR T‑cell platform, GlyTR (pronounced 'glitter'), engineered to target tumor‑associated carbohydrate antigens that are highly expressed across a broad range of cancers. Unlike traditional high‑affinity antibody based CAR designs, GlyTR uses a unique "velcro‑like" lectin binding mechanism that enables selective elimination of cancer cells while minimizing off‑tumor toxicity and expanding the potential of CAR‑T therapy into solid tumors where safety has historically been a major barrier.
-
ProBio And GCP ClinPlus Partner To Accelerate Clinical Trials In China
11/4/2026
ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development solutions for global biopharma customers.
-
ProBio De-Risks Cell & Gene Therapy With New Packaging Test
11/4/2026
To address the critical need for accelerated decision-making and de-risked progression from discovery to Chemistry, Manufacturing, and Controls (CMC) in cell and gene therapy programs, ProBio Inc. has launched its new Viral Vector Packaging Test. This early-stage development offering provides biopharma innovators with essential data and technical confidence, strengthening ProBio's end-to-end capabilities in advanced therapies.
-
Boehringer Ingelheim And SBP Group Enter Partnership To Advance Next-Generation Cancer Therapies
11/4/2026
Boehringer Ingelheim, headquartered in Germany, and Sino Biopharmaceutical Limited (01177.HK; together with its subsidiaries, “SBP Group”) today announced a strategic multi-program option and license agreement to advance potential next-generation cancer treatments based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies.
-
Minghui Pharmaceutical And ASKA Pharmaceutical Enter Into Exclusive License Agreement For The IGF-1R Antibody In Japan
11/4/2026
Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan.
-
Spektus Pharma And GEBRO Holding Announce Global Commercialization Partnership For ActraFlex®
11/3/2026
Spektus Pharma Inc. ("Spektus") and GEBRO Holding GmbH ("GEBRO") today announced a strategic global commercialization partnership for ActraFlex®, a novel twice-daily extended-release formulation of tramadol and paracetamol for pain management.
-
Merck To Divest CDMO Business To Lonza
11/3/2026
Merck, a leading science and technology company, has signed a definitive agreement to divest its contract development and manufacturing organization (CDMO) business within its Life Science business sector to Lonza.